Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Bayer Aktienges ADR (BAYRY)

Bayer Aktienges ADR (BAYRY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 53,561,760
  • Shares Outstanding, K 3,929,696
  • Annual Sales, $ 52,152 M
  • Annual Income, $ 1,183 M
  • 60-Month Beta 1.08
  • Price/Sales 1.11
  • Price/Cash Flow 5.15
  • Price/Book 1.37
Trade BAYRY with:
  • Price/Earnings ttm 6.76
  • Earnings Per Share ttm 2.14
  • Most Recent Earnings 0.99 on 05/10/22
  • Next Earnings Date 08/04/22
  • Annual Dividend & Yield 0.35 (2.40%)
  • Most Recent Dividend 0.352 on 05/02/22
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate 0.27
  • Number of Estimates 1
  • High Estimate 0.27
  • Low Estimate 0.27
  • Prior Year 0.31
  • Growth Rate Est. (year over year) -12.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.5000 +0.96%
on 07/14/22
15.0500 -9.44%
on 07/19/22
-0.7300 (-5.08%)
since 07/05/22
3-Month
13.5000 +0.96%
on 07/14/22
18.0099 -24.32%
on 06/06/22
-2.3500 (-14.71%)
since 05/05/22
52-Week
12.4500 +9.48%
on 12/03/21
18.4500 -26.12%
on 04/11/22
-0.1780 (-1.29%)
since 08/05/21

Most Recent Stories

More News
Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q2

Bayer (BAYRY) beats estimates for both earnings and revenues in the second quarter of 2022.

REGN : 613.61 (-0.22%)
JNJ : 171.11 (-0.40%)
BAYRY : 13.6300 (-7.09%)
DTIL : 1.7400 (+3.57%)
Regeneron (REGN) Q2 Earnings & Sales Beat on Eylea, Dupixent

Regeneron (REGN) tops earnings and sales in the second quarter, driven by its lead drug Eylea and profits from asthma drug Dupixent. However, earnings decline year over year.

REGN : 613.61 (-0.22%)
SNY : 49.71 (+1.08%)
RHHBY : 41.1600 (-0.10%)
BAYRY : 13.6300 (-7.09%)
What Did We Learn from the Q2 GDP Growth Report?

Is U.S. economic growth slowing, or not?

BAYRY : 13.6300 (-7.09%)
ULTA : 377.80 (+1.46%)
CRWD : 191.17 (+1.02%)
Novavax (NVAX) to Report Q2 Earnings: What's in the Cards?

On Novavax's (NVAX) second-quarter earnings call, investors' focus is likely to be on the sales figures of its COVID-19 vaccine.

AZN : 66.03 (-0.39%)
BAYRY : 13.6300 (-7.09%)
NVAX : 60.27 (-2.68%)
IONS : 45.70 (+5.57%)
CRISPR (CRSP) to Report Q2 Earnings: What's in the Cards?

On CRISPR Therapeutics' (CRSP) Q2 earnings call, investors will look for updates on its pipeline candidates, especially its lead candidate exa-cel.

AZN : 66.03 (-0.39%)
VRTX : 288.03 (+4.80%)
BAYRY : 13.6300 (-7.09%)
CRSP : 81.40 (+3.16%)
Will AstraZeneca (AZN) Deliver a Beat This Earnings Season?

Strong demand trends for AstraZeneca's (AZN) key drugs, Lynparza, Tagrisso, Imfinzi and Farxiga are likely to have driven the top line in the second quarter.

AZN : 66.03 (-0.39%)
GILD : 61.09 (-1.32%)
BAYRY : 13.6300 (-7.09%)
BNTX : 183.11 (+1.48%)
Pfizer (PFE) to Report Q2 Earnings: What's in the Cards?

Revenues from the COVID-19 vaccine and COVID pill, Paxlovid are likely to have driven Pfizer's (PFE) sales in the second quarter.

AZN : 66.03 (-0.39%)
PFE : 49.27 (-1.18%)
BAYRY : 13.6300 (-7.09%)
BNTX : 183.11 (+1.48%)
AbbVie (ABBV) to Report Q2 Earnings: What's in the Cards?

AbbVie's (ABBV) second-quarter results are expected to reflect the impact of strong demand for immunology drugs, aesthetics and cosmetics products. Investors are likely to enquire on ABBV's plans to counter...

AZN : 66.03 (-0.39%)
JNJ : 171.11 (-0.40%)
BAYRY : 13.6300 (-7.09%)
ABBV : 138.04 (-0.63%)
Merck (MRK) to Report Q2 Earnings: What's in the Cards?

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and COVID-19 antiviral pill, molnupiravir when the company reports Q2 earnings.

AZN : 66.03 (-0.39%)
MRK : 87.41 (+0.68%)
BAYRY : 13.6300 (-7.09%)
BNTX : 183.11 (+1.48%)
GSK Gears Up to Report Q2 Earnings: What's in the Cards?

The newer respiratory and HIV drugs of GSK are likely to have driven second-quarter sales. The performance of Xevudy, GSK's monoclonal antibody for COVID-19, remains to be seen when the company reports....

AZN : 66.03 (-0.39%)
GSK : 40.57 (-0.07%)
BAYRY : 13.6300 (-7.09%)
VIR : 30.17 (+3.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 14.2150
2nd Resistance Point 14.0620
1st Resistance Point 13.8460
Last Price 13.6300
1st Support Level 13.4770
2nd Support Level 13.3240
3rd Support Level 13.1080

See More

52-Week High 18.4500
Fibonacci 61.8% 16.1580
Fibonacci 50% 15.4500
Fibonacci 38.2% 14.7420
Last Price 13.6300
52-Week Low 12.4500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar